Skip to content

Vasopressin and V2 Receptor in Meniere's Disease

Vasopressin and V2 Receptor in Meniere's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00599560
Enrollment
135
Registered
2008-01-23
Start date
1998-04-30
Completion date
2005-09-30
Last updated
2016-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere Disease

Keywords

Meniere's disease, stress, vasopressin, endolymphatic sac, V2 receptor, cyclic AMP, Plasma vasopressin level and V2R mRNA expression level in the endolymphatic sac both were significantly higher in patients with Meniere's disease., In Meniere's disease, there were significant negative co-relationships between vasopressin and V2R., The cyclic AMP activity was basically up-regulated in the endolymphatic sac in Meniere's disease.., The cyclic AMP sensitivity for vasopressin was significantly elevated in the endolymphatic sac in Meniere's disease.

Brief summary

Summary: Some of sicknesses are well known to be provoked by inadequate adaptation to physical and/or psychogenic stress in their daily life. Meniere's disease is also a common inner ear disease accompanied with vertigo, hearing loss and tinnitus especially in civilized people under stressed life style. Its oto-pathology was firstly revealed in 1938 to be inner ear endolymphatic hydrops through the temporal bone study. To elucidate the neuroscientific relationship between stress and inner ear, we examined plasma vasopressin (the anti-diuretic stress hormone) and its receptor, V2R in the endolymphatic sac (the inner ear endo-organ for endolymph absorption) in Meniere's patients.

Detailed description

Methods: Between 1998 and 2006, we enrolled and assigned 105 intractable Meniere's patients to examine plasma vasopressin during remission of vertigo attacks (controls: 30 patients with chronic otitis media). Using the real-time PCR method, we examined V2R mRNA expression in the endolymphatic sac in 12 patients (controls: 6 patients with acoustic neurinoma). By means of cell culture and cyclic AMP assay, we also examined cyclic AMP activity in the endolymphatic sac in 3 patients (controls: 3 patients with acoustic neurinoma).

Interventions

GENETICvasopressin, V2 receptor and cyclic AMP

plasma vasopressin, V2 receptor, cyclic AMP

Sponsors

Osaka City University
CollaboratorOTHER
Osaka University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1. Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2. Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.

Exclusion criteria

* Any other neuro-otologic diseases.

Design outcomes

Primary

MeasureTime frame
plasma vasopressin level and V2 receptor mRNA in the endolymphatic sac in Meniere's disease vs controlsprospective

Secondary

MeasureTime frame
cyclic AMP activity in the endolymphatic sac in Meniere's disease vs controlsprospective

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026